Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
183
days
Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development
Authors
Abigail Dirks; Sylviane de Viron; Kenneth McFarlane; Kenneth A. GetzShow moreShow less
Affiliations
1. Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, USA; 2. Clue Points S.A, Louvain-la-Neuve, Belgium; 3. CluePoints Inc, King of Prussia, USAShow moreShow less
44
days
Identifying and Deploying Benchmarks for Clinical Research at Sites
Authors
Rida Momin; Laura Mangiarini; Alexandre Dias Tavares Costa; Carla Peacock; Emaad Shariff; Sara Noorain; Jennifer Preston; Sabah AttarShow moreShow less
Affiliations
1. Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK; 2. Fondazione Penta ETS, Padova, Italy; 3. Instituto Carlos Chagas (ICC/Fiocruz Paraná), Rio de Janeiro, Brazil; 4. Innovate R Ltd., Manchester, UK; 5. Groundmark Learning, Leamington Spa, UK; 6. University of Liverpool, Liverpool, UKShow moreShow less
104
days
Real-World Evidence for Drug Approvals: Moving Toward Greater Regulatory Clarity
Authors
Tala H. Fakhouri; Rasika Kalamegham; Nicole Mahoney; Rose Purcell; Mike D’AmbrosioShow moreShow less
Affiliations
1. Parexel International, Maryland, USA; 2. Genentech, Washington, DC, USA; 3. Novartis, Rockville, USA; 4. Takeda, Washington, DC, USAShow moreShow less
270
days
Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials
Authors
Marina Alacoque Rodrigues; Cristiane Aparecida Menezes de Pádua; Paula Lana de Miranda Drummond; Jéssica Soares Malta; Adriano Max Moreira ReisShow moreShow less
Affiliations
1. College of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; 2. Fundação Ezequiel Dias, Belo Horizonte, BrazilShow moreShow less
130
days
Advancing Wider Implementation of Multi-regional Clinical Trials in East Asia
Authors
John H. Skerritt; Irene Chan; Aloka ChakravartyShow moreShow less
Affiliations
1. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia; 2. Eli Lilly and Co, Indianapolis, USAShow moreShow less
140
days
Pharmacovigilance Data From Digital Health Systems: Regulations, Implications, and Opportunities—A TransCelerate Perspective
Authors
James Whitehead; Rajesh Ghosh; Anna Monaco; Jackie Grissinger; Inessa Neyman; Tom Umrath; Clint CraunShow moreShow less
Affiliations
1. AstraZeneca, Newmarket, England, UK; 2. Genentech/Hoffman LaRoche Ltd., South San Francisco, USA; 3. Merck & Co., Inc., Rahway, USA; 4. Johnson & Johnson, New Brunswick, USA; 5. Pfizer Global Pharmaceuticals, New York, USA; 6. Novartis Pharmaceuticals Corporation, East Hanover, USA; 7. TransCelerate BioPharma Inc., West Conshohocken, USAShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days